© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to March
oral lung penetrant RSV fusion inhibitor
Ph. II candidate (50 mg BID) for RSV infect.
opt. from literature starting point
J. Med. Chem., Mar. 17, 2021
Reviral Ltd, Hertfordshire, UK
The Reviral respiratory syncytial virus (RSV) fusion inhibitor (sisunatovir) is an oral Ph. II clinical candidate that demonstrated reduction in viral load and total symptom score in RSV-infected patients…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.